Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines. [electronic resource]
Producer: 20190124Description: 823-835 p. digitalISSN:- 1756-8927
- Antineoplastic Agents -- pharmacology
- Cell Line, Tumor
- Drug Resistance, Neoplasm
- G1 Phase -- drug effects
- Humans
- Leukemia, Myeloid, Acute -- drug therapy
- Mitogen-Activated Protein Kinase Kinases -- antagonists & inhibitors
- Mutation
- Protein Kinase Inhibitors -- pharmacology
- fms-Like Tyrosine Kinase 3 -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.